Kodiak Sciences Inc (KOD) - Total Assets
Based on the latest financial reports, Kodiak Sciences Inc (KOD) holds total assets worth $306.01 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Kodiak Sciences Inc balance sheet independence to measure how much of total assets are equity-financed.
Kodiak Sciences Inc - Total Assets Trend (2016–2025)
This chart illustrates how Kodiak Sciences Inc's total assets have evolved over time, based on quarterly financial data. Explore Kodiak Sciences Inc long-term investment allocation to see how much of total assets are deployed in long-term investments.
Kodiak Sciences Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Kodiak Sciences Inc's total assets of $306.01 Million consist of 61.1% current assets and 38.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 59.7% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how Kodiak Sciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Kodiak Sciences Inc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Kodiak Sciences Inc's current assets represent 61.1% of total assets in 2025, a decrease from 84.1% in 2016.
- Cash Position: Cash and equivalents constituted 59.7% of total assets in 2025, down from 79.4% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Kodiak Sciences Inc Competitors by Total Assets
Key competitors of Kodiak Sciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Kodiak Sciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.54 | 4.62 | 21.56 |
| Quick Ratio | 3.54 | 4.62 | 21.56 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $125.69 Million | $111.81 Million | $843.31 Million |
Kodiak Sciences Inc - Advanced Valuation Insights
This section examines the relationship between Kodiak Sciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 17.29 |
| Latest Market Cap to Assets Ratio | 5.53 |
| Asset Growth Rate (YoY) | 4.8% |
| Total Assets | $351.53 Million |
| Market Capitalization | $1.94 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Kodiak Sciences Inc's assets at a significant premium (5.53x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Kodiak Sciences Inc's assets grew by 4.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Kodiak Sciences Inc (2016–2025)
The table below shows the annual total assets of Kodiak Sciences Inc from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $351.53 Million | +4.75% |
| 2024-12-31 | $335.58 Million | -30.00% |
| 2023-12-31 | $479.37 Million | -28.09% |
| 2022-12-31 | $666.63 Million | -26.28% |
| 2021-12-31 | $904.22 Million | -15.28% |
| 2020-12-31 | $1.07 Billion | +197.42% |
| 2019-12-31 | $358.87 Million | +289.27% |
| 2018-12-31 | $92.19 Million | +2741.83% |
| 2017-12-31 | $3.24 Million | -73.22% |
| 2016-12-31 | $12.11 Million | -- |
About Kodiak Sciences Inc
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in… Read more